Grail

What Grail does

GRAIL, Inc. (Nasdaq: GRAL) is a publicly traded healthcare company developing Galleri, a multi-cancer early detection (MCED) blood test that screens for signals from more than 50 cancer types — including many deadly cancers without recommended screening — from a single blood draw. Founded in 2016 as a spin-out of Illumina, GRAIL became an independent public company in June 2024 following FTC- and European Commission–mandated divestiture. The company operates from Menlo Park, California, with additional clinical lab and operations capacity in Research Triangle Park, North Carolina, and research/policy offices in London and Washington, D.C., supported by 501–1,000 employees. The Galleri test is currently offered as a Laboratory Developed Test under CLIA certification and CAP accreditation, with a premarket approval application filed with the FDA in January 2026 and Medicare reimbursement scheduled to begin in 2028 under the Nancy Gardner Sewell MCED Coverage Act. The underlying technology analyzes methylation patterns on cell-free DNA fragments using next-generation sequencing combined with proprietary machine learning classifiers that identify cancer-derived DNA and predict cancer signal origin with >90% accuracy.

GRAIL generates revenue primarily from per-test Galleri sales at a $949 list price, supplemented by a $699/year subscription channel via Hims & Hers Health Labs, biopharma research services through the GRAIL Cancer Research Solution (a research-use-only methylation platform for companion diagnostics, MRD, and treatment monitoring), and real-world evidence generated from its 380,000+ participant clinical program. Its go-to-market is a hybrid model combining direct-to-consumer sales via galleri.com, enterprise sales to leading US health systems and academic medical centers (Cleveland Clinic, Mayo Clinic, Providence, Sutter, Henry Ford, Intermountain, Ochsner, Dana-Farber, OHSU, among others), EHR-integrated ordering through Epic (~450 health systems) and athenahealth, distribution partnerships (Quest Diagnostics, Junction, Superpower, Samsung C&T for Asia-Pacific), and insurance/employer benefit channels (John Hancock, Curative, BeniComp, TRICARE). The company raised approximately $325M in a private placement in October 2025 and $110M in a Samsung-led equity financing in mid-2026, supporting a cash runway that extends into 2030. Recent results include 2025 total revenue of $147M and Q1 2026 revenue of $40.8M (+28% YoY) with Galleri test volume of 56,000+ (+50% YoY), though the NHS-Galleri trial's primary endpoint miss in February 2026 triggered a 50%+ stock decline and a securities class action.

Name

Grail

Legal name

GRAIL, Inc.

Website

https://grail.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

GRAIL (Nasdaq: GRAL) is a publicly traded healthcare company that develops Galleri, a multi-cancer early detection blood test screening for 50+ cancer types, serving US health systems, biopharma partners, and consumers primarily in the United States with planned Asia-Pacific expansion.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics (Multi-Cancer Early Detection)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413), Scientific Research and Development Services (5417)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro primary industry

Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing (HLAAANAG)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Prognostic & Risk Stratification Biomarkers (disease progression, recurrence risk) (HLAAAMAF), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

Keywords

• Multi-cancer early detection
• Cancer screening blood test
• Methylation-based diagnostics
• Clinical laboratory services
• Precision oncology research

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Galleri Test Sales: Direct per-test revenue from sales of the Galleri multi-cancer early detection test at $949 list price; prescribed by physicians and administered as a blood draw. Q1 2026 Galleri test revenue was $39.8M (+37% YoY), with test volume exceeding 56,000 (+50% YoY); 2025 Galleri test revenue was $138–139 million, up from $109 million in 2024
2. Partner Subscription Channels: Recurring annual revenue through subscription-based distribution partnerships such as Hims & Hers Health Labs ($699/year, $250 discount to list price), expanding recurring revenue motion
3. Biopharma Research Services: Research-use-only methylation-based ctDNA platform services, companion diagnostic development, and biomarker collaborations with leading biopharma partners (e.g., AstraZeneca) across the oncology drug development continuum
4. Real-World Evidence and Data Insights: Evidence generation from population-scale clinical program (>380,000 participants) supporting payer reimbursement, regulatory filings (FDA PMA submitted January 2026), and value-based healthcare positioning

Pricing tiers

Go-to-market motion8 records

Distribution channels11 records

Marketing channels9 records

Core offering

GRAIL develops and commercializes the Galleri multi-cancer early detection (MCED) blood test, which screens for cancer signals from more than 50 cancer types through a single blood draw using a proprietary targeted methylation platform combined with machine learning classifiers. The test is sold in the U.S. by prescription at a list price of $949 and is also offered through health system, insurer, employer, digital health, and government channels. GRAIL additionally offers a research-use-only Cancer Research Solution to biopharma partners for ctDNA-based detection, classification, and quantification in precision oncology applications.

Differentiator

Problem solved

Functional benefit

Brands

• Galleri: Galleri is GRAIL's flagship multi-cancer early detection (MCED) blood test, a registered trademark of GRAIL, Inc., capable of screening for signals from more than 50 cancer types with a single blood draw.

Products and services

• Galleri Test A first-of-its-kind multi-cancer early detection (MCED) blood test that screens for more than 50 cancer types — including many deadly cancers without recommended screening options (e.g., pancreatic, ovarian, liver/bile duct) — by detecting cancer-derived DNA methylation signals from a single blood draw and predicting cancer signal origin with greater than 90% accuracy. Available by prescription only in the U.S.; recommended for adults with elevated cancer risk such as those aged 50 or older.
• GRAIL Cancer Research Solution A research-use-only (RUO) methylation-based ctDNA platform offered to biopharma partners supporting companion diagnostic development, clinical trial stratification, biomarker discovery, risk stratification, minimal residual disease (MRD) assessment, and treatment monitoring across the cancer care continuum.

Quantifiable outcome

• PATHFINDER 2: Galleri increased cancer detection 6.5-fold when added to USPSTF A and B recommended screenings; 71% of new cancers detected by Galleri were in stages I-III; 60.3% PPV; 99.6% specificity (false positive rate <0.4%); 91.3% Cancer Signal Origin accuracy
• +3 more outcomes

Named customers26 records

Segments7 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability4 records

Feature8 records

Partnerships

15 partnerships are on record, tiered core, flagship and minor.

• JunctioncoreTechnology or Integration · 19 April 2026Collaboration to enable scalable access to the Galleri MCED test across digital health and clinical organizations through Junction's diagnostic operations platform, supporting test ordering, physician network support, and workflow integration across multiple states.
• athenahealthcoreStrategic or Co-development Partner · 9 April 2026Collaboration to enable streamlined provider ordering of the Galleri multi-cancer early detection test through athenahealth's EHR platform, simplifying the integration of MCED testing into routine clinical practice.
• EpicflagshipStrategic or Co-development Partner · 7 April 2026Strategic collaboration to integrate the Galleri multi-cancer early detection test into Epic's electronic health record platform, enabling approximately 450 US health systems to order and receive test results within existing clinical workflows. Implementation planning began Q1 2026 with broad availability expected by end of 2026. Ochsner Health cited as an early adopter health system.
• SuperpowercoreStrategic or Co-development Partner · 1 April 2026Strategic partnership to provide Galleri MCED test access to Superpower members within its proactive preventative health platform, paired with biomarker testing, AI-powered insights, and clinical care teams for comprehensive cancer risk assessment. PATHFINDER 2 showed Galleri increased cancer detection more than seven-fold when added to standard screening.
• Hims & Hers HealthflagshipChannel Partner/ Reseller/ Distributor · 4 February 2026Distribution partnership adding the Galleri MCED test to the Hims & Hers Labs product at $699 per year (a $250 discount to Galleri's $949 list price), available exclusively to Labs subscribers. The Galleri test is central to Hims & Hers' upcoming Super Bowl ad campaign, marking a strategic pivot toward preventive oncology offerings.
• Quest DiagnosticsflagshipChannel Partner/ Reseller/ Distributor · 1 February 2025Distribution partnership making the Galleri MCED test available through the Quest Diagnostics ordering platform to streamline the provider-patient experience and broaden access to Galleri via Quest's national diagnostic footprint.
• University of OxfordcoreStrategic or Co-development Partner · 1 January 2025Academic research partnership with the University of Oxford on the SYMPLIFY study — the first prospective study of a multi-cancer early detection test in a symptomatic patient population. Long-term SYMPLIFY data presented at the Early Detection of Cancer Conference (EDCC) in October 2025. Results published in The Lancet Oncology in June 2023.
• Curative Insurance CompanycoreChannel Partner/ Reseller/ Distributor · 1 February 2024Added Galleri test to member health plan benefits with no out-of-pocket cost for members, expanding zero-cost access to MCED screening for insured populations.
• BeniCompminorChannel Partner/ Reseller/ Distributor · 1 January 2024Added GRAIL's MCED test as part of BeniComp's employee health screening benefits, extending preventive cancer screening access through employer benefit programs.
• Whitman-Walker Institute and Cancer Support CommunityminorStrategic or Co-development Partner · 1 August 2023Collaborative research aimed at advancing health equity in cancer screening and care through multi-cancer early detection, with focus on underserved populations.
• John HancockcoreChannel Partner/ Reseller/ Distributor · 1 September 2022First life insurance carrier to offer access to GRAIL's multi-cancer early detection test to its customers, expanding the insurance channel for preventive oncology screening.
• AstraZenecaflagshipStrategic or Co-development Partner · 1 June 2022Strategic collaboration with AstraZeneca to develop companion diagnostic tests to enable the treatment of early-stage cancer using GRAIL's methylation-based technology. Also partnered on a novel risk classification test for use in an AstraZeneca lung cancer study (announced March 2024). Partnerships support biopharma applications across the cancer care continuum including risk stratification, MRD, treatment monitoring, and clinical trial stratification.
• U.S. Department of Veterans Affairs / Veterans Health FoundationcoreStrategic or Co-development Partner · 1 May 2022Collaboration with the U.S. Department of Veterans Affairs and the Veterans Health Foundation to evaluate the Galleri MCED test, including the REFLECTION real-world evidence study with veterans having toxic exposure and veteran-focused research aimed at advancing health equity in cancer screening.
• Providence Health & ServicesflagshipChannel Partner/ Reseller/ Distributor · 1 March 2021First healthcare system to offer Galleri test to patients in March 2021, serving as flagship launch partner for the commercial MCED test and demonstrating clinical integration into a major US health system.
• NHS England (UK National Health Service)flagshipStrategic or Co-development Partner · 1 November 2020Multi-year clinical partnership with NHS England on the NHS-Galleri trial — the first and only randomized controlled trial of a multi-cancer early detection test — enrolling 142,250 asymptomatic participants aged 50-77 across England. Also includes the SYMPLIFY study with the University of Oxford for symptomatic patient population. The trial demonstrated a 14% reduction in Stage IV cancer diagnoses.

Scale indicators20 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Exact Sciences: Exact Sciences is a direct peer in cancer screening diagnostics, best known for Cologuard, the leading non-invasive colorectal cancer screening test sold via prescription. Both companies compete in the broader cancer screening market and pursue multi-cancer and single-cancer blood-based detection, sharing providers, channels, and payer relationships.
• Guardant Health: Guardant Health is a direct peer in liquid biopsy and ctDNA-based oncology diagnostics, offering Guardant360 for tumor profiling and Shield for colorectal cancer screening. Both companies apply next-generation sequencing to cell-free DNA for cancer detection and pursue biopharma research services revenue.
• Natera: Natera is a direct peer in cell-free DNA-based testing, with a Signatera MRD test and growing oncology pipeline. Both companies leverage cfDNA/molecular residual disease technology for oncology applications and sell into biopharma and clinical research channels.
• Exact Sciences (Thrive/LDT): Exact Sciences acquired Thrive Earlier Detection to enter MCED, and previously developed the Cancerseek test, making it a direct competitor pursuing the same multi-cancer early detection opportunity. Both companies target asymptomatic screening populations and aim for FDA approval and broad payer coverage.

Emerging players

• Freenome: Freenome is an emerging MCED competitor developing a blood-based test for early colorectal cancer detection using a multiomics (genomic, epigenomic, proteomic) platform. It is pursuing large clinical validation studies (PREEMPT CRC) and represents direct competitive pressure on GRAIL's broader MCED opportunity.
• Personalis: Personalis is an emerging player in cancer genomics offering the NeXT Personal liquid biopsy assay for MRD and tumor profiling. It overlaps with GRAIL's biopharma RUO platform and ctDNA-based oncology applications, particularly in MRD detection and treatment monitoring.
• Singlera Genomics: Singlera Genomics is an emerging player in MCED that developed the PanSeer assay and has pursued early-cancer detection in China. It represents competitive pressure in the multi-cancer detection category, particularly for GRAIL's Asia-Pacific expansion plans.

Broad incumbents

• Tempus AI: Tempus is a broad incumbent in precision medicine and AI-driven oncology diagnostics, offering sequencing, molecular profiling, and biopharma data services. While not a direct MCED competitor, Tempus competes for biopharma R&D spend and increasingly for clinical decision support in oncology.
• Foundation Medicine (Roche): Foundation Medicine is a broad incumbent in comprehensive genomic profiling for solid tumors, owned by Roche. It competes with GRAIL's biopharma research services and overlaps in ctDNA-based oncology applications, though it focuses on tissue and blood profiling for treatment selection rather than screening.

Regional players

• Burning Rock Biotech: Burning Rock is a regional player in China focused on NGS-based cancer diagnostics and early detection. It represents GRAIL's most direct international (Asia) peer for ctDNA-based oncology testing, competing for biopharma research partnerships and cancer screening adoption in the Chinese market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/GrailBio
• Facebookfacebook.com/grailbio
• LinkedInlinkedin.com/company/grail-inc.

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles21 records

Subsidiaries1 record

Funding overview

Funding rounds7 records

Investors29 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Grail